Literature DB >> 9487550

Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats.

S Kagatani1, N Inaba, M Fukui, T Sonobe.   

Abstract

PURPOSE: The long-term stability and nasal absorption characteristics of a basic nasal formulation of azetirelin, a thyrotropin-releasing hormone analog and its absorption enhancement by incorporation of acylcarnitines in the formulation were investigated.
METHODS: The long-term stability of basic nasal azetirelin formulations at 25 degrees C was predicted by calculation from the Arrhenius plot of the data on 6 months' storage at 40, 50 and 60 degrees C. Nasal azetirelin absorption characteristics were kinetically examined by intranasal administration to rats, determination of plasma azetirelin level by radioimmunoassay, and fitting the data to a two-compartment model including absorption rate.
RESULTS: Basic nasal azetirelin formulations of pH 4.0 and pH 5.1 were predicted to be highly stable. Residual azetirelin after 2 years storage at 25 degrees C was greater than 95%. Nasal absorption characteristics of this formulation in the pH 4.0-6.3 range showed pH-dependency, with pH 4.0 showing the highest absolute bioavailability (Bioav) of 17.1%. This nasal Bioav was 21 times greater than that of oral administration (0.8%). Acylcarnitines with 12 or more carbon atoms in the acyl chain greatly enhanced nasal absorption of azetirelin: Bioavs with lauroylcarnitine chloride (LCC) and palmitoylcarnitine chloride were 96.9% and 72.9%, respectively. This enhancement by LCC plateaued at the low concentration of 0.1%.
CONCLUSIONS: The basic nasal azetirelin formulation at pH 4.0 is stable and shows adequate absorption, with nasal absorption having greater Bioav than oral absorption. The 12-carbon acylate LCC was the strongest enhancer among acylcarnitines and provided near-total delivery of the administered dose to the blood.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9487550     DOI: 10.1023/a:1011952804479

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Nasal absorption of insulin in dogs.

Authors:  S Harai; T Ikenaga; T Matsuzawa
Journal:  Diabetes       Date:  1978-03       Impact factor: 9.461

2.  Effects of a new TRH analogue, YM-14673 on the central nervous system.

Authors:  M Yamamoto; M Shimizu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

3.  Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid.

Authors:  P Langguth; H P Merkle; G L Amidon
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

4.  Role of carnitine in fatty acid metabolism of normal and ischemic myocardium.

Authors:  L H Opie
Journal:  Am Heart J       Date:  1979-03       Impact factor: 4.749

5.  Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcarnitines.

Authors:  E L LeCluyse; L E Appel; S C Sutton
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

6.  Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.

Authors:  S Kagatani; T Shinoda; M Fukui; T Ohmura; S Hasumi; T Sonobe
Journal:  Pharm Res       Date:  1996-05       Impact factor: 4.200

7.  Absorption of thyrotropin-releasing hormone after oral administration of TRH tartrate monohydrate in the rat, dog and human.

Authors:  S Yokohama; K Yamashita; H Toguchi; J Takeuchi; N Kitamori
Journal:  J Pharmacobiodyn       Date:  1984-02

8.  In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine.

Authors:  J H Hochman; J A Fix; E L LeCluyse
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

9.  Changes in plasma thyrotrophin-releasing hormone, thyrotrophin, prolactin and thyroid hormone levels after intravenous, intranasal or rectal administration of synthetic thyrotrophin-releasing hormone in man.

Authors:  T Mitsuma; T Nogimori
Journal:  Acta Endocrinol (Copenh)       Date:  1984-10

10.  Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. I. Possible factors for the low oral bioavailability in rats.

Authors:  I Sasaki; T Fujita; M Murakami; A Yamamoto; E Nakamura; H Imasaki; S Muranishi
Journal:  Biol Pharm Bull       Date:  1994-09       Impact factor: 2.233

View more
  3 in total

1.  Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.

Authors:  S Ahmed; A P Sileno; J C deMeireles; R Dua; H K Pimplaskar; W J Xia; J Marinaro; E Langenback; F J Matos; L Putcha; V D Romeo; C R Behl
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Loss of the V-ATPase B1 subunit isoform expressed in non-neuronal cells of the mouse olfactory epithelium impairs olfactory function.

Authors:  Teodor G Păunescu; Steven Rodriguez; Eric Benz; Mary McKee; Robert Tyszkowski; Mark W Albers; Dennis Brown
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.